Profile Image
Harel Dahari Photo
Harel Dahari
Associate Professor
Primary Department
Advanced Degrees
Bar Ilan University , Ramat Gan , FR , Israel
Translational Research
Dahari,H.; Boodram,B.How to eliminate HCV in people who inject drugs in the USA The Lancet.Infectious diseases 2018 ;18(2):134-135
Reinharz,V.; Dahari,H.; Barash,D.Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics Mathematical biosciences 2018 ;300:1-13
Boodram,B.; Hotton,A. L.; Shekhtman,L.; Gutfraind,A.; Dahari,H.High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members Journal of urban health : bulletin of the New York Academy of Medicine 2018 ;95(1):71-82
Major, M; Gutfraind, A; Shekhtman, L; Cui, Q; Kachko, A; Cotler, SJ; Hajarizadeh, B; Sacks-Davis, R; Page, K; Boodram, B; Dahari, HModeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users. Science translational medicine 2018 ;10(449)
Kumberger, P; Durso-Cain, K; Uprichard, SL; Dahari, H; Graw, FAccounting for Space—Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models. Viruses 2018 ;10(4)
Ishida,Y.; Chung,T. L.; Imamura,M.; Hiraga,N.; Sen,S.; Yokomichi,H.; Tateno,C.; Canini,L.; Perelson,A. S.; Uprichard,S. L.; Dahari,H.; Chayama,K.Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics Hepatology (Baltimore, Md.) 2018 ; :
Goyal,A.; Lurie,Y.; Meissner,E. G.; Major,M.; Sansone,N.; Uprichard,S. L.; Cotler,S. J.; Dahari,H.Modeling HCV cure after an ultra-short duration of therapy with direct acting agents Antiviral Research 2017 ;144:281-285
Canini,L.; Imamura,M.; Kawakami,Y.; Uprichard,S. L.; Cotler,S. J.; Dahari,H.; Chayama,K.HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients PLoS ONE 2017 ;12(12):e0187409
Canini,L.; Koh,C.; Cotler,S. J.; Uprichard,S. L.; Winters,M. A.; Han,M. A. T.; Kleiner,D. E.; Idilman,R.; Yurdaydin,C.; Glenn,J. S.; Heller,T.; Dahari,H.Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection Hepatology communications 2017 ;1(4):288-292
Malespin,M.; Benyashvili,T.; Uprichard,S. L.; Perelson,A. S.; Dahari,H.; Cotler,S. J.Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies Therapeutic advances in gastroenterology 2017 ;10(1):68-73
Shteyer,E.; Dahari,H.; Gafanovich,I.; Dery,I.; Wolf,D.; Cotler,S. J.; Lurie,Y.End of treatment RNA-positive/sustained viral response in an individual with acute hepatitis C virus infection treated with direct-acting antivirals Therapeutic advances in gastroenterology 2017 ;10(5):429-430
Hasin,Y.; Shteingart,S.; Dahari,H.; Gafanovich,I.; Floru,S.; Braun,M.; Shlomai,A.; Verstandig,A.; Dery,I.; Uprichard,S. L.; Cotler,S. J.; Lurie,Y.Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report WORLD JOURNAL OF HEPATOLOGY 2016 ;8(20):858-862
Dahari,H.; Canini,L.; Graw,F.; Uprichard,S. L.; Araujo,E. S.; Penaranda,G.; Coquet,E.; Chiche,L.; Riso,A.; Renou,C.; Bourliere,M.; Cotler,S. J.; Halfon,P.HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir Journal of Hepatology 2016 ; :
DebRoy,S.; Hiraga,N.; Imamura,M.; Hayes,C. N.; Akamatsu,S.; Canini,L.; Perelson,A. S.; Pohl,R. T.; Persiani,S.; Uprichard,S. L.; Tateno,C.; Dahari,H.; Chayama,K.Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy Journal of viral hepatitis 2016 ; :
Dahari,H.; Cotler,S. J.; Feld,J. J.Cure prevents more than transmission of HCV Hepatology (Baltimore, Md.) 2016 ; :
Dahari,H.; Halfon,P.; Cotler,S. J.Resurrection of response-guided therapy for sofosbuvir combination therapies Journal of Hepatology 2016 ; :
Dahari,H.; Shteingart,S.; Gafanovich,I.; Cotler,S. J.; D'Amato,M.; Pohl,R. T.; Weiss,G.; Ashkenazi,Y. J.; Tichler,T.; Goldin,E.; Lurie,Y.Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics Liver international : official journal of the International Association for the Study of the Liver 2015 ;35(2):289-294
Guedj, J; Canini, L; Cotler, S; Dahari, HReply: To PMID 25098971. Hepatology (Baltimore, Md.) 2015 ;61(6)
Canini, L; DebRoy, S; Mariño, Z; Conway, JM; Crespo, G; Navasa, M; D'Amato, M; Ferenci, P; Cotler, SJ; Forns, X; Perelson, AS; Dahari, HSeverity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. ANTIVIRAL THERAPY 2015 ;20(2)
Koh,C.; Canini,L.; Dahari,H.; Zhao,X.; Uprichard,S. L.; Haynes-Williams,V.; Winters,M. A.; Subramanya,G.; Cooper,S. L.; Pinto,P.; Wolff,E. F.; Bishop,R.; Ai Thanda Han,M.; Cotler,S. J.; Kleiner,D. E.; Keskin,O.; Idilman,R.; Yurdaydin,C.; Glenn,J. S.; Heller,T.Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial The Lancet.Infectious diseases 2015 ;15(10):1167-1174
Gutfraind,A.; Boodram,B.; Prachand,N.; Hailegiorgis,A.; Dahari,H.; Major,M. E.Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections PLoS ONE 2015 ;10(9):e0137993
Graw,F.; Martin,D. N.; Perelson,A. S.; Uprichard,S. L.; Dahari,H.Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach Journal of virology 2015 ;89(13):6551-6561
Echevarria,D.; Gutfraind,A.; Boodram,B.; Major,M.; Del Valle,S.; Cotler,S. J.; Dahari,H.Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago PLoS ONE 2015 ;10(8):e0135901
Guedj,J.; Rotman,Y.; Cotler,S. J.; Koh,C.; Schmid,P.; Albrecht,J.; Haynes-Williams,V.; Liang,T. J.; Hoofnagle,J. H.; Heller,T.; Dahari,H.Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling Hepatology (Baltimore, Md.) 2014 ;60(6):1902-1910
Dahari,H.; Cotler,S. J.Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach Hepatology (Baltimore, Md.) 2014 ;59(6):2422-2423
Rotman,Y.; Noureddin,M.; Feld,J. J.; Guedj,J.; Witthaus,M.; Han,H.; Park,Y. J.; Park,S. H.; Heller,T.; Ghany,M. G.; Doo,E.; Koh,C.; Abdalla,A.; Gara,N.; Sarkar,S.; Thomas,E.; Ahlenstiel,G.; Edlich,B.; Titerence,R.; Hogdal,L.; Rehermann,B.; Dahari,H.; Perelson,A. S.; Hoofnagle,J. H.; Liang,T. J.Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C Gut 2014 ;63(1):161-169
Rong, L; Guedj, J; Dahari, H; Perelson, ASTreatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. ANTIVIRAL THERAPY 2014 ;19(5)
Zhang,J.; Lipton,H. L.; Perelson,A. S.; Dahari,H.Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection Journal of virology 2013 ;87(7):4052-4059
Rong,L.; Guedj,J.; Dahari,H.; Coffield,D. J.,Jr; Levi,M.; Smith,P.; Perelson,A. S.Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model PLoS computational biology 2013 ;9(3):e1002959
Polyak,S. J.; Oberlies,N. H.; Pecheur,E. I.; Dahari,H.; Ferenci,P.; Pawlotsky,J. M.Silymarin for HCV infection ANTIVIRAL THERAPY 2013 ;18(2):141-147
Guedj,J.; Dahari,H.; Rong,L.; Sansone,N. D.; Nettles,R. E.; Cotler,S. J.; Layden,T. J.; Uprichard,S. L.; Perelson,A. S.Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proceedings of the National Academy of Sciences of the United States of America 2013 ;110(10):3991-3996
Guedj,J.; Dahari,H.; Uprichard,S. L.; Perelson,A. S.The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate Expert review of gastroenterology & hepatology 2013 ;7(5):397-399
Dahari,H.; Cotler,S. J.; Layden,T. J.; Perelson,A. S.Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling Journal of Hepatology 2013 ;58(4):840-842
Sabahi,A.; Marsh,K. A.; Dahari,H.; Corcoran,P.; Lamora,J. M.; Yu,X.; Garry,R. F.; Uprichard,S. L.The rate of hepatitis C virus infection initiation in vitro is directly related to particle density Virology 2010 ;407(1):110-119
Dahari,H.; Sainz,B.,Jr; Perelson,A. S.; Uprichard,S. L.Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon Journal of virology 2009 ;83(13):6383-6390